This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
PFE Talzenna Combo Shows Strong Efficacy in Wider Prostate Cancer Use
by Zacks Equity Research
Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.
PFENegative Net Change INONegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
by Zacks Equity Research
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.
NVOPositive Net Change INONegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development
by Kinjel Shah
OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.
RGNXNegative Net Change KRYSPositive Net Change OCGNNegative Net Change
biotechs
Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data
by Kinjel Shah
Ocugen faces rising cash burn and dilution risk as it advances late-stage gene therapy programs, with 2026-2027 data and filings set to drive volatility.
RGNXNegative Net Change KRYSPositive Net Change OCGNNegative Net Change
biotechs pharmaceuticals
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
by Zacks Equity Research
XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
ANIPNegative Net Change XENENo Net Change INDVPositive Net Change
biotechs
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
by Ahan Chakraborty
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
REGNPositive Net Change ALNYPositive Net Change PFENegative Net Change BBIOPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?
by Sundeep Ganoria
AbbVie stock sinks 5% as J&J's newly approved Icotyde raises competitive concerns for blockbuster Skyrizi in the fast-growing IL-23 market.
JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
Sanofi's Venglustat Wins FDA Breakthrough Tag for Gaucher Disease
by Zacks Equity Research
SNY wins FDA Breakthrough tag for venglustat in GD3 after phase III data showed significant neurological gains in Gaucher disease patients.
SNYNegative Net Change ANIPNegative Net Change INDVPositive Net Change
biotechs
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
by Zacks Equity Research
PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.
RHHBYPositive Net Change PBYINegative Net Change ANIPNegative Net Change PHATNegative Net Change
biotechs
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
by Zacks Equity Research
Aldeyra Therapeutics stock plunges 71% after the FDA issues a third CRL for the resubmitted reproxalap NDA for the treatment of dry eye disease.
ADMANegative Net Change ALDXNegative Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals